Switzerland Diabetes Market projected to reach US$ 1.99 Billion by 2028, due to factors like the rising prevalence of diabetes, technological advancements, healthcare expenditure, government initiatives, and research and development efforts
05 Jun, 2023

Renub Research has recently issued a report titled "Switzerland Diabetes Market, Size, Forecast 2023-2028, By SMBG Device, Continuous Glucose Monitoring (CGM), Insulin Pen, Insulin Pump, and Company Analysis" providing a comprehensive analysis of the industry that includes market share insights. In addition, the report comprises competitor and regional research and contemporary extension in the Switzerland Diabetes Market. Switzerland Diabetes Market will propel a CAGR of about 4.71% from 2023 to 2028.

Switzerland faces the challenge of diabetes, with a prevalence of 4.6% among individuals aged 20 to 79, according to the World Bank. The impact of diabetes on the health, well-being, and productivity of the Swiss population is substantial. The complications arising from this disease have far-reaching effects on the resilience of health systems and incur significant costs across Switzerland. It is evident that effectively managing diabetes must be prioritized on a national scale in Switzerland. This chronic health condition, characterized by elevated blood sugar levels, affects most Swiss people.

Like in other developed nations, modern lifestyles contribute to the rise in diabetes in Switzerland, with sedentary work environments and decreased physical activity becoming common. In addition, unhealthy dietary habits, such as high consumption of processed foods, sugary beverages, and a lack of fruits, vegetables, and whole grains, further contribute to the risk of diabetes. These lifestyle and dietary changes have played a significant role in the increasing growth of the Switzerland diabetes market.

Switzerland diabetes market is witnessing growth due to advancements in diabetes management technologies, addressing the demand for efficient solutions among healthcare providers and patients. The country's strong healthcare system, coupled with its emphasis on diabetes prevention, diagnosis, and treatment, drives the increased demand for diabetes-related products and services. Genetic predisposition and the thriving pharmaceutical and biotechnology sectors in Switzerland also contribute to the prevalence of diabetes and fuel the expansion of the diabetes market. Moreover, Switzerland's dedication to innovation introduces new therapies, medications, and diagnostic tools, further stimulating the growth of the diabetes market in the country.

Type 2 diabetes is prevalent in Switzerland due to high aging and obesity rates

According to Swiss Medical Net, type 2 diabetes, the most common form of the disease, affects approximately half million individuals in Switzerland. In contrast, around 40,000 people in the country are affected by type 1 diabetes. These statistics highlight the significant prevalence of type-2 diabetes compared to type-1 diabetes in Switzerland. Like other developed countries, Switzerland has an aging population, with one-fifth expected to be 65 or older in the coming years. 

This demographic shift increases the risk of developing type 2 diabetes as age is an essential factor. Also, Switzerland has witnessed an increase in obesity rates over time, with projections by World Obesity Federation estimating that 37% of the adult population will be obese by 2035. In addition, socioeconomic factors, such as lower education levels, lower income, and limited healthcare access, can impact diabetes prevalence by hindering healthy lifestyle choices and effective disease management. Therefore, understanding these factors is crucial for developing strategies to prevent, detect, and manage type-2 diabetes in Switzerland.

Government Initiatives Taken to curb diabetes in Switzerland

Switzerland's Health2030 Strategy, adopted in December 2019, builds upon Health2030, and addresses new priority areas in health policy. Despite high life expectancy and healthcare access, there is an increasing prevalence of care-intensive diseases and financial difficulties in affording health insurance, resulting in unequal health opportunities based on socioeconomic status. The Federal Council aims to enhance the healthcare system to ensure high-quality and affordable healthcare for all.

Health2030 provides a framework for action, guiding stakeholders. Additionally, the Swiss government has implemented initiatives to tackle diabetes, including the National Diabetes Strategy, health promotion programs, public awareness campaigns, and collaboration with healthcare professionals and stakeholders. These initiatives focus on prevention, early detection, management, and education to improve diabetes outcomes and promote healthy lifestyles.

Report Details:

Insulin pens dominate the Switzerland diabetes market due to their convenience and precise dosage delivery, resulting in improved blood sugar control

Insulin pens have revolutionized diabetes management by providing a convenient and safe method of insulin administration. These devices eliminate the need for vials and needles, reducing the risk of needle stick injuries and improving overall safety. With features such as adjustable dosing, memory functions, and built-in needle safety mechanisms, insulin pens offer a user-friendly experience and promote treatment adherence.

In Switzerland, a variety of insulin pens are available to meet the needs of individuals with diabetes. Examples include Humulin® KwikPen and NovoPen® 4, which offer both rapid-acting and intermediate-acting insulin formulations, Apidra® FlexTouch for rapid-acting insulin, and Lantus® SoloStar for intermediate-acting insulin. These pens provide precise insulin delivery, allowing individuals to manage their diabetes effectively.

Pharmaceutical companies and healthcare professionals in Switzerland have actively marketed insulin pens, contributing to their popularity among patients. The portability and discreetness of these pens make them particularly suitable for active individuals and frequent travellers. Additionally, insulin pens are cost-effective, requiring less insulin compared to vials, and are often covered by insurance, making them an affordable option for diabetes management.

Devices – The Switzerland Diabetes Market breakup in 4 points

1.    Continuous Glucose Monitoring (CGM)
2.    Self-Monitoring Blood Glucose (SMBG)
3.    Insulin Pen
4.    Insulin Pump

Switzerland Diabetes Market - Devices Sub-Segment Analysis

Continuous Glucose Monitoring (CGM)

1.    Glucose Sensor Market & Forecast
2.    CGM Transmitter Market & Forecast
3.    CGM User
4.    CGM Reimbursement

Self Monitoring Blood Glucose (SMBG)

1.    Test Strips Market and Forecast
2.    Lancet Market and Forecast
3.    Meter Market and Forecast
4.    Blood Glucose (SMBG) Users
5.    Blood Glucose Devices Reimbursement

Insulin Pen

1.    Disposable Insulin Pen
2.    Reusable Insulin Pen
3.    Smart Insulin Pen
4.    Insulin Pen Needle Market
5.    Insulin Pen Users
6.    Reimbursement Policies

Insulin Pump

1.    Insulin Pump Market
2.    Insulin Pump Users
3.    Insulin Pump Products
4.    Reimbursement Policies

Competitive Landscape

The key players in the Switzerland Diabetes Market include B. Braun Melsungen AG, Sanofi, Eli Lilly and Company, Becton Dickenson (BD), Novo Nordisk A/S, Ypsomed AG, Biocon, Medtronic, Insulet Corporation, Abbott Laboratories, Terumo Corporation, and Dexcom Inc.

Companies in the Switzerland Diabetes Market Report have been studied from 3 Points.

•    Company Overview
•    Recent Developments
•    Financial Insight

Company Analysis

1.    B. Braun Melsungen AG
2.    Eli Lilly and Company
3.    Terumo Corporation
4.    Becton, Dickinson (BD)
5.    Novo Nardisk
6.    Ypsomed AG
7.    Medtronic
8.    InsuletCororation
9.    Abbott Laboratories
10.    DarioHealth Crop
11.    Dexcom, Inc
12.    Roche Diagnostic
13.    Tandem Diabetes Care